Antares Pharma, Inc. (NASDAQ: ATRS) Stock Competitors & Peer Comparison
See ATRS's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for ATRS and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ATRS | $5.59 | +0.18% | 0 | 14.95 | $0.37 | N/A |
| ISRG | $369.15 | +2.41% | 130.4B | 38.37 | $9.62 | N/A |
| BDXA | $59.24 | -2.24% | 55.9B | 45.70 | $1.30 | +2.25% |
| BDX | $177.85 | +0.81% | 49B | 13.68 | $13.00 | +2.25% |
| RMD | $218.27 | -0.60% | 31.7B | 20.26 | $10.77 | +1.13% |
| MDLN | $32.53 | +0.43% | 27.5B | 23.84 | $1.36 | N/A |
| WST | $346.23 | +0.58% | 24.4B | 40.71 | $8.50 | +0.25% |
| HOLX | $76.01 | +0.00% | 17B | 31.54 | $2.41 | N/A |
| SOLV | $87.45 | -0.23% | 15.1B | 12.32 | $7.10 | N/A |
| BDXB | $48.16 | +1.39% | 13.7B | 7.60 | $6.33 | +2.25% |
Stock Comparison
Intuitive Surgical, Inc. (NASDAQ: ISRG)
ATRS vs ISRG Comparison September 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, ISRG has a market cap of 130.4B. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while ISRG trades at $369.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas ISRG's P/E ratio is 38.37. In terms of profitability, ATRS's ROE is +0.31%, compared to ISRG's ROE of +0.18%. Regarding short-term risk, ATRS is less volatile compared to ISRG. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check ISRG's competition here
Becton, Dickinson and Company (NYSE: BDXA)
ATRS vs BDXA Comparison September 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, BDXA has a market cap of 55.9B. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas BDXA's P/E ratio is 45.70. In terms of profitability, ATRS's ROE is +0.31%, compared to BDXA's ROE of +0.04%. Regarding short-term risk, ATRS is less volatile compared to BDXA. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check BDXA's competition here
Becton, Dickinson and Company (NYSE: BDX)
ATRS vs BDX Comparison September 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, BDX has a market cap of 49B. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while BDX trades at $177.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas BDX's P/E ratio is 13.68. In terms of profitability, ATRS's ROE is +0.31%, compared to BDX's ROE of +0.04%. Regarding short-term risk, ATRS is less volatile compared to BDX. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check BDX's competition here
ResMed Inc. (NYSE: RMD)
ATRS vs RMD Comparison September 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, RMD has a market cap of 31.7B. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while RMD trades at $218.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas RMD's P/E ratio is 20.26. In terms of profitability, ATRS's ROE is +0.31%, compared to RMD's ROE of +0.24%. Regarding short-term risk, ATRS is less volatile compared to RMD. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check RMD's competition here
Medline Inc. (NASDAQ: MDLN)
ATRS vs MDLN Comparison September 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, MDLN has a market cap of 27.5B. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while MDLN trades at $32.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas MDLN's P/E ratio is 23.84. In terms of profitability, ATRS's ROE is +0.31%, compared to MDLN's ROE of +0.05%. Regarding short-term risk, ATRS is less volatile compared to MDLN. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check MDLN's competition here
West Pharmaceutical Services, Inc. (NYSE: WST)
ATRS vs WST Comparison September 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, WST has a market cap of 24.4B. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while WST trades at $346.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas WST's P/E ratio is 40.71. In terms of profitability, ATRS's ROE is +0.31%, compared to WST's ROE of +0.19%. Regarding short-term risk, ATRS is less volatile compared to WST. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check WST's competition here
Hologic, Inc. (NASDAQ: HOLX)
ATRS vs HOLX Comparison September 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, HOLX has a market cap of 17B. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while HOLX trades at $76.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas HOLX's P/E ratio is 31.54. In terms of profitability, ATRS's ROE is +0.31%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, ATRS is more volatile compared to HOLX. This indicates higher risk in terms of short-term price fluctuations for ATRS.Check HOLX's competition here
Solventum Corporation (NYSE: SOLV)
ATRS vs SOLV Comparison September 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, SOLV has a market cap of 15.1B. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while SOLV trades at $87.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas SOLV's P/E ratio is 12.32. In terms of profitability, ATRS's ROE is +0.31%, compared to SOLV's ROE of +0.29%. Regarding short-term risk, ATRS is less volatile compared to SOLV. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check SOLV's competition here
Becton, Dickinson and Company (NYSE: BDXB)
ATRS vs BDXB Comparison September 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas BDXB's P/E ratio is 7.60. In terms of profitability, ATRS's ROE is +0.31%, compared to BDXB's ROE of +0.04%. Regarding short-term risk, ATRS is less volatile compared to BDXB. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check BDXB's competition here
Baxter International Inc. (NYSE: BAX)
ATRS vs BAX Comparison September 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, BAX has a market cap of 12.3B. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while BAX trades at $23.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas BAX's P/E ratio is 11.44. In terms of profitability, ATRS's ROE is +0.31%, compared to BAX's ROE of -0.17%. Regarding short-term risk, ATRS is less volatile compared to BAX. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check BAX's competition here
The Cooper Companies, Inc. (NASDAQ: COO)
ATRS vs COO Comparison September 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, COO has a market cap of 10.5B. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while COO trades at $53.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas COO's P/E ratio is 11.82. In terms of profitability, ATRS's ROE is +0.31%, compared to COO's ROE of +0.07%. Regarding short-term risk, ATRS is less volatile compared to COO. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check COO's competition here
Avantor, Inc. (NYSE: AVTR)
ATRS vs AVTR Comparison September 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, AVTR has a market cap of 10B. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while AVTR trades at $14.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas AVTR's P/E ratio is 17.42. In terms of profitability, ATRS's ROE is +0.31%, compared to AVTR's ROE of -0.10%. Regarding short-term risk, ATRS is less volatile compared to AVTR. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check AVTR's competition here
Repligen Corporation (NASDAQ: RGEN)
ATRS vs RGEN Comparison September 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, RGEN has a market cap of 9.3B. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while RGEN trades at $165.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas RGEN's P/E ratio is 91.77. In terms of profitability, ATRS's ROE is +0.31%, compared to RGEN's ROE of +0.02%. Regarding short-term risk, ATRS is less volatile compared to RGEN. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check RGEN's competition here
AptarGroup, Inc. (NYSE: ATR)
ATRS vs ATR Comparison September 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, ATR has a market cap of 8B. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while ATR trades at $124.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas ATR's P/E ratio is 21.83. In terms of profitability, ATRS's ROE is +0.31%, compared to ATR's ROE of +0.14%. Regarding short-term risk, ATRS is less volatile compared to ATR. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check ATR's competition here
Bausch + Lomb Corporation (NYSE: BLCO)
ATRS vs BLCO Comparison September 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, BLCO has a market cap of 6.2B. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while BLCO trades at $17.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas BLCO's P/E ratio is 26.54. In terms of profitability, ATRS's ROE is +0.31%, compared to BLCO's ROE of -0.03%. Regarding short-term risk, ATRS is less volatile compared to BLCO. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check BLCO's competition here
Teleflex Incorporated (NYSE: TFX)
ATRS vs TFX Comparison September 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, TFX has a market cap of 5.8B. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while TFX trades at $130.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas TFX's P/E ratio is 14.98. In terms of profitability, ATRS's ROE is +0.31%, compared to TFX's ROE of -0.32%. Regarding short-term risk, ATRS is less volatile compared to TFX. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check TFX's competition here
Stevanato Group S.p.A. (NYSE: STVN)
ATRS vs STVN Comparison September 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, STVN has a market cap of 5.7B. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while STVN trades at $20.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas STVN's P/E ratio is 31.61. In terms of profitability, ATRS's ROE is +0.31%, compared to STVN's ROE of +0.09%. Regarding short-term risk, ATRS is less volatile compared to STVN. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check STVN's competition here
Merit Medical Systems, Inc. (NASDAQ: MMSI)
ATRS vs MMSI Comparison September 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, MMSI has a market cap of 5.2B. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while MMSI trades at $86.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas MMSI's P/E ratio is 22.09. In terms of profitability, ATRS's ROE is +0.31%, compared to MMSI's ROE of +0.09%. Regarding short-term risk, ATRS is less volatile compared to MMSI. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check MMSI's competition here
Envista Holdings Corp (NYSE: NVST)
ATRS vs NVST Comparison September 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, NVST has a market cap of 4.2B. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while NVST trades at $25.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas NVST's P/E ratio is 17.38. In terms of profitability, ATRS's ROE is +0.31%, compared to NVST's ROE of +0.04%. Regarding short-term risk, ATRS is less volatile compared to NVST. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check NVST's competition here
ICU Medical, Inc. (NASDAQ: ICUI)
ATRS vs ICUI Comparison September 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, ICUI has a market cap of 3.9B. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while ICUI trades at $156.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas ICUI's P/E ratio is 19.54. In terms of profitability, ATRS's ROE is +0.31%, compared to ICUI's ROE of +0.01%. Regarding short-term risk, ATRS is less volatile compared to ICUI. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check ICUI's competition here
Pulse Biosciences, Inc. (NASDAQ: PLSE)
ATRS vs PLSE Comparison September 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, PLSE has a market cap of 3.7B. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while PLSE trades at $53.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas PLSE's P/E ratio is -45.01. In terms of profitability, ATRS's ROE is +0.31%, compared to PLSE's ROE of -0.94%. Regarding short-term risk, ATRS is less volatile compared to PLSE. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check PLSE's competition here
AtriCure, Inc. (NASDAQ: ATRC)
ATRS vs ATRC Comparison September 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, ATRC has a market cap of 2.8B. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while ATRC trades at $54.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas ATRC's P/E ratio is 1693.79. In terms of profitability, ATRS's ROE is +0.31%, compared to ATRC's ROE of +0.02%. Regarding short-term risk, ATRS is less volatile compared to ATRC. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check ATRC's competition here
DENTSPLY SIRONA Inc. (NASDAQ: XRAY)
ATRS vs XRAY Comparison September 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, XRAY has a market cap of 2.1B. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while XRAY trades at $10.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas XRAY's P/E ratio is 7.31. In terms of profitability, ATRS's ROE is +0.31%, compared to XRAY's ROE of -0.40%. Regarding short-term risk, ATRS is less volatile compared to XRAY. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check XRAY's competition here
LeMaitre Vascular, Inc. (NASDAQ: LMAT)
ATRS vs LMAT Comparison September 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, LMAT has a market cap of 1.8B. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while LMAT trades at $80.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas LMAT's P/E ratio is 29.63. In terms of profitability, ATRS's ROE is +0.31%, compared to LMAT's ROE of +0.16%. Regarding short-term risk, ATRS is less volatile compared to LMAT. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check LMAT's competition here
BioLife Solutions, Inc. (NASDAQ: BLFS)
ATRS vs BLFS Comparison September 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, BLFS has a market cap of 1.7B. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while BLFS trades at $34.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas BLFS's P/E ratio is -165.37. In terms of profitability, ATRS's ROE is +0.31%, compared to BLFS's ROE of +0.13%. Regarding short-term risk, ATRS is less volatile compared to BLFS. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check BLFS's competition here
Azenta, Inc. (NASDAQ: AZTA)
ATRS vs AZTA Comparison September 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, AZTA has a market cap of 1.4B. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while AZTA trades at $30.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas AZTA's P/E ratio is 73.45. In terms of profitability, ATRS's ROE is +0.31%, compared to AZTA's ROE of -0.08%. Regarding short-term risk, ATRS is less volatile compared to AZTA. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check AZTA's competition here
Kestra Medical Technologies, Ltd. (NASDAQ: KMTS)
ATRS vs KMTS Comparison September 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, KMTS has a market cap of 1.3B. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while KMTS trades at $22.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas KMTS's P/E ratio is -9.68. In terms of profitability, ATRS's ROE is +0.31%, compared to KMTS's ROE of -0.59%. Regarding short-term risk, ATRS is less volatile compared to KMTS. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check KMTS's competition here
STAAR Surgical Company (NASDAQ: STAA)
ATRS vs STAA Comparison September 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, STAA has a market cap of 1.1B. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while STAA trades at $22.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas STAA's P/E ratio is 39.75. In terms of profitability, ATRS's ROE is +0.31%, compared to STAA's ROE of +0.01%. Regarding short-term risk, ATRS is less volatile compared to STAA. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check STAA's competition here
Atrion Corporation (NASDAQ: ATRI)
ATRS vs ATRI Comparison September 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas ATRI's P/E ratio is 64.50. In terms of profitability, ATRS's ROE is +0.31%, compared to ATRI's ROE of +0.08%. Regarding short-term risk, ATRS is more volatile compared to ATRI. This indicates higher risk in terms of short-term price fluctuations for ATRS.Check ATRI's competition here
AngioDynamics, Inc. (NASDAQ: ANGO)
ATRS vs ANGO Comparison September 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, ANGO has a market cap of 631.1M. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while ANGO trades at $15.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas ANGO's P/E ratio is -39.15. In terms of profitability, ATRS's ROE is +0.31%, compared to ANGO's ROE of -0.21%. Regarding short-term risk, ATRS is less volatile compared to ANGO. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check ANGO's competition here
Sanara MedTech Inc. (NASDAQ: SMTI)
ATRS vs SMTI Comparison September 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, SMTI has a market cap of 321M. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while SMTI trades at $34.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas SMTI's P/E ratio is -582.00. In terms of profitability, ATRS's ROE is +0.31%, compared to SMTI's ROE of -4.74%. Regarding short-term risk, ATRS is less volatile compared to SMTI. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check SMTI's competition here
Embecta Corp. (NASDAQ: EMBC)
ATRS vs EMBC Comparison September 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, EMBC has a market cap of 293.1M. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while EMBC trades at $4.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas EMBC's P/E ratio is 1.90. In terms of profitability, ATRS's ROE is +0.31%, compared to EMBC's ROE of -0.14%. Regarding short-term risk, ATRS is less volatile compared to EMBC. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check EMBC's competition here
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN)
ATRS vs NNNN Comparison September 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, NNNN has a market cap of 278.3M. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while NNNN trades at $6.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas NNNN's P/E ratio is 91.62. In terms of profitability, ATRS's ROE is +0.31%, compared to NNNN's ROE of +0.27%. Regarding short-term risk, ATRS is less volatile compared to NNNN. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check NNNN's competition here
OraSure Technologies, Inc. (NASDAQ: OSUR)
ATRS vs OSUR Comparison September 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, OSUR has a market cap of 223.8M. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while OSUR trades at $3.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas OSUR's P/E ratio is -4.71. In terms of profitability, ATRS's ROE is +0.31%, compared to OSUR's ROE of -0.15%. Regarding short-term risk, ATRS is less volatile compared to OSUR. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check OSUR's competition here
Utah Medical Products, Inc. (NASDAQ: UTMD)
ATRS vs UTMD Comparison September 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, UTMD has a market cap of 222M. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while UTMD trades at $69.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas UTMD's P/E ratio is 20.62. In terms of profitability, ATRS's ROE is +0.31%, compared to UTMD's ROE of +0.09%. Regarding short-term risk, ATRS is less volatile compared to UTMD. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check UTMD's competition here
Pro-Dex, Inc. (NASDAQ: PDEX)
ATRS vs PDEX Comparison September 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, PDEX has a market cap of 200.5M. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while PDEX trades at $62.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas PDEX's P/E ratio is 15.21. In terms of profitability, ATRS's ROE is +0.31%, compared to PDEX's ROE of +0.31%. Regarding short-term risk, ATRS is less volatile compared to PDEX. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check PDEX's competition here
KORU Medical Systems, Inc. (NASDAQ: KRMD)
ATRS vs KRMD Comparison September 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, KRMD has a market cap of 145.1M. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while KRMD trades at $3.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas KRMD's P/E ratio is -79.00. In terms of profitability, ATRS's ROE is +0.31%, compared to KRMD's ROE of -0.11%. Regarding short-term risk, ATRS is less volatile compared to KRMD. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check KRMD's competition here
Stereotaxis, Inc. (AMEX: STXS)
ATRS vs STXS Comparison September 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, STXS has a market cap of 126.3M. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while STXS trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas STXS's P/E ratio is -7.59. In terms of profitability, ATRS's ROE is +0.31%, compared to STXS's ROE of -1.33%. Regarding short-term risk, ATRS is less volatile compared to STXS. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check STXS's competition here
Daxor Corporation (NASDAQ: DXR)
ATRS vs DXR Comparison September 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, DXR has a market cap of 67M. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while DXR trades at $11.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas DXR's P/E ratio is 9.33. In terms of profitability, ATRS's ROE is +0.31%, compared to DXR's ROE of +0.13%. Regarding short-term risk, ATRS is less volatile compared to DXR. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check DXR's competition here
Akoya Biosciences, Inc. (NASDAQ: AKYA)
ATRS vs AKYA Comparison September 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas AKYA's P/E ratio is -1.34. In terms of profitability, ATRS's ROE is +0.31%, compared to AKYA's ROE of -1.80%. Regarding short-term risk, ATRS is more volatile compared to AKYA. This indicates higher risk in terms of short-term price fluctuations for ATRS.Check AKYA's competition here
SkyAI, Inc. (NASDAQ: STSS)
ATRS vs STSS Comparison September 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, STSS has a market cap of 53.7M. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while STSS trades at $1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas STSS's P/E ratio is -0.02. In terms of profitability, ATRS's ROE is +0.31%, compared to STSS's ROE of -1.54%. Regarding short-term risk, ATRS is less volatile compared to STSS. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check STSS's competition here
Singular Genomics Systems, Inc. (NASDAQ: OMIC)
ATRS vs OMIC Comparison September 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas OMIC's P/E ratio is -0.58. In terms of profitability, ATRS's ROE is +0.31%, compared to OMIC's ROE of -0.43%. Regarding short-term risk, ATRS is more volatile compared to OMIC. This indicates higher risk in terms of short-term price fluctuations for ATRS.Check OMIC's competition here
GlucoTrack, Inc. (NASDAQ: IGAP)
ATRS vs IGAP Comparison September 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas IGAP's P/E ratio is -10.52. In terms of profitability, ATRS's ROE is +0.31%, compared to IGAP's ROE of +1.80%. Regarding short-term risk, ATRS is less volatile compared to IGAP. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check IGAP's competition here
Precision Optics Corporation, Inc. (NASDAQ: POCI)
ATRS vs POCI Comparison September 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, POCI has a market cap of 48.7M. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while POCI trades at $4.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas POCI's P/E ratio is -7.06. In terms of profitability, ATRS's ROE is +0.31%, compared to POCI's ROE of -0.37%. Regarding short-term risk, ATRS is less volatile compared to POCI. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check POCI's competition here
Nephros, Inc. (NASDAQ: NEPH)
ATRS vs NEPH Comparison September 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, NEPH has a market cap of 48.5M. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while NEPH trades at $4.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas NEPH's P/E ratio is 74.50. In terms of profitability, ATRS's ROE is +0.31%, compared to NEPH's ROE of +0.16%. Regarding short-term risk, ATRS is less volatile compared to NEPH. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check NEPH's competition here
Milestone Scientific Inc. (AMEX: MLSS)
ATRS vs MLSS Comparison September 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, MLSS has a market cap of 38.2M. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while MLSS trades at $0.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas MLSS's P/E ratio is -8.65. In terms of profitability, ATRS's ROE is +0.31%, compared to MLSS's ROE of -1.49%. Regarding short-term risk, ATRS is less volatile compared to MLSS. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check MLSS's competition here
Harvard Bioscience, Inc. (NASDAQ: HBIO)
ATRS vs HBIO Comparison September 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, HBIO has a market cap of 36.2M. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while HBIO trades at $8.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas HBIO's P/E ratio is -22.31. In terms of profitability, ATRS's ROE is +0.31%, compared to HBIO's ROE of -0.92%. Regarding short-term risk, ATRS is less volatile compared to HBIO. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check HBIO's competition here
SmileDirectClub, Inc. (NASDAQ: SDC)
ATRS vs SDC Comparison September 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas SDC's P/E ratio is -0.03. In terms of profitability, ATRS's ROE is +0.31%, compared to SDC's ROE of -1.96%. Regarding short-term risk, ATRS is less volatile compared to SDC. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check SDC's competition here
Invacare Corporation (NYSE: IVC)
ATRS vs IVC Comparison September 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas IVC's P/E ratio is -0.79. In terms of profitability, ATRS's ROE is +0.31%, compared to IVC's ROE of -0.46%. Regarding short-term risk, ATRS is less volatile compared to IVC. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check IVC's competition here
Retractable Technologies, Inc. (AMEX: RVP)
ATRS vs RVP Comparison September 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, RVP has a market cap of 20.4M. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while RVP trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas RVP's P/E ratio is -5.67. In terms of profitability, ATRS's ROE is +0.31%, compared to RVP's ROE of -0.05%. Regarding short-term risk, ATRS is less volatile compared to RVP. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check RVP's competition here
Jin Medical International Ltd. (NASDAQ: ZJYL)
ATRS vs ZJYL Comparison September 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, ZJYL has a market cap of 16.2M. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while ZJYL trades at $2.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas ZJYL's P/E ratio is 14.16. In terms of profitability, ATRS's ROE is +0.31%, compared to ZJYL's ROE of +0.04%. Regarding short-term risk, ATRS is less volatile compared to ZJYL. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check ZJYL's competition here
Bionano Genomics, Inc. (NASDAQ: BNGO)
ATRS vs BNGO Comparison September 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, BNGO has a market cap of 14M. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while BNGO trades at $1.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas BNGO's P/E ratio is -0.28. In terms of profitability, ATRS's ROE is +0.31%, compared to BNGO's ROE of -0.79%. Regarding short-term risk, ATRS is less volatile compared to BNGO. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check BNGO's competition here
Regentis Biomaterials Ltd. (AMEX: RGNT)
ATRS vs RGNT Comparison September 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, RGNT has a market cap of 13.4M. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while RGNT trades at $1.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas RGNT's P/E ratio is -0.08. In terms of profitability, ATRS's ROE is +0.31%, compared to RGNT's ROE of N/A. Regarding short-term risk, ATRS is less volatile compared to RGNT. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check RGNT's competition here
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (NASDAQ: CUPR)
ATRS vs CUPR Comparison September 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, CUPR has a market cap of 8.5M. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while CUPR trades at $3.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas CUPR's P/E ratio is -2.30. In terms of profitability, ATRS's ROE is +0.31%, compared to CUPR's ROE of -15.69%. Regarding short-term risk, ATRS is less volatile compared to CUPR. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check CUPR's competition here
Femasys Inc. (NASDAQ: FEMY)
ATRS vs FEMY Comparison September 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, FEMY has a market cap of 8.4M. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while FEMY trades at $2.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas FEMY's P/E ratio is -0.62. In terms of profitability, ATRS's ROE is +0.31%, compared to FEMY's ROE of -2.26%. Regarding short-term risk, ATRS is less volatile compared to FEMY. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check FEMY's competition here
Lucyd, Inc (NASDAQ: LUCY)
ATRS vs LUCY Comparison September 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, LUCY has a market cap of 5.3M. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while LUCY trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas LUCY's P/E ratio is -0.49. In terms of profitability, ATRS's ROE is +0.31%, compared to LUCY's ROE of -0.89%. Regarding short-term risk, ATRS is less volatile compared to LUCY. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check LUCY's competition here
NanoString Technologies, Inc. (NASDAQ: NSTG)
ATRS vs NSTG Comparison September 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas NSTG's P/E ratio is -0.03. In terms of profitability, ATRS's ROE is +0.31%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, ATRS is less volatile compared to NSTG. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check NSTG's competition here
Predictive Oncology Inc. (NASDAQ: POAI)
ATRS vs POAI Comparison September 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, POAI has a market cap of 3.6M. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while POAI trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas POAI's P/E ratio is -0.03. In terms of profitability, ATRS's ROE is +0.31%, compared to POAI's ROE of -21.19%. Regarding short-term risk, ATRS is less volatile compared to POAI. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check POAI's competition here
NEXGEL, Inc. (NASDAQ: NXGL)
ATRS vs NXGL Comparison September 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, NXGL has a market cap of 2.5M. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while NXGL trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas NXGL's P/E ratio is -0.42. In terms of profitability, ATRS's ROE is +0.31%, compared to NXGL's ROE of -1.33%. Regarding short-term risk, ATRS is less volatile compared to NXGL. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check NXGL's competition here
Meihua International Medical Technologies Co., Ltd. (NASDAQ: MHUA)
ATRS vs MHUA Comparison September 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, MHUA has a market cap of 2.4M. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while MHUA trades at $7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas MHUA's P/E ratio is 0.25. In terms of profitability, ATRS's ROE is +0.31%, compared to MHUA's ROE of +0.07%. Regarding short-term risk, ATRS is more volatile compared to MHUA. This indicates higher risk in terms of short-term price fluctuations for ATRS.Check MHUA's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVD)
ATRS vs GMVD Comparison September 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas GMVD's P/E ratio is -0.01. In terms of profitability, ATRS's ROE is +0.31%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, ATRS is less volatile compared to GMVD. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check GMVD's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVDW)
ATRS vs GMVDW Comparison September 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas GMVDW's P/E ratio is N/A. In terms of profitability, ATRS's ROE is +0.31%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, ATRS is less volatile compared to GMVDW. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check GMVDW's competition here
Avinger, Inc. (NASDAQ: AVGR)
ATRS vs AVGR Comparison September 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas AVGR's P/E ratio is -0.05. In terms of profitability, ATRS's ROE is +0.31%, compared to AVGR's ROE of +17.82%. Regarding short-term risk, ATRS is less volatile compared to AVGR. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check AVGR's competition here
NEXGEL, Inc. (NASDAQ: NXGLW)
ATRS vs NXGLW Comparison September 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, NXGLW has a market cap of 1M. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while NXGLW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas NXGLW's P/E ratio is -0.02. In terms of profitability, ATRS's ROE is +0.31%, compared to NXGLW's ROE of -1.33%. Regarding short-term risk, ATRS is less volatile compared to NXGLW. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check NXGLW's competition here
Lucyd, Inc (NASDAQ: LUCYW)
ATRS vs LUCYW Comparison September 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, LUCYW has a market cap of 296.1K. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas LUCYW's P/E ratio is N/A. In terms of profitability, ATRS's ROE is +0.31%, compared to LUCYW's ROE of -0.89%. Regarding short-term risk, ATRS is less volatile compared to LUCYW. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check LUCYW's competition here
IntriCon Corporation (NASDAQ: IIN)
ATRS vs IIN Comparison September 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, IIN has a market cap of 0. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas IIN's P/E ratio is 226.45. In terms of profitability, ATRS's ROE is +0.31%, compared to IIN's ROE of -0.00%. Regarding short-term risk, ATRS is more volatile compared to IIN. This indicates higher risk in terms of short-term price fluctuations for ATRS.Check IIN's competition here
Analogic Corporation (NASDAQ: ALOG)
ATRS vs ALOG Comparison September 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, ALOG has a market cap of 0. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while ALOG trades at $83.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas ALOG's P/E ratio is 40.93. In terms of profitability, ATRS's ROE is +0.31%, compared to ALOG's ROE of -0.15%. Regarding short-term risk, ATRS is more volatile compared to ALOG. This indicates higher risk in terms of short-term price fluctuations for ATRS.Check ALOG's competition here
Apria, Inc. (NASDAQ: APR)
ATRS vs APR Comparison September 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, APR has a market cap of 0. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas APR's P/E ratio is 22.59. In terms of profitability, ATRS's ROE is +0.31%, compared to APR's ROE of +9.81%. Regarding short-term risk, ATRS is more volatile compared to APR. This indicates higher risk in terms of short-term price fluctuations for ATRS.Check APR's competition here
Invuity, Inc. (NASDAQ: IVTY)
ATRS vs IVTY Comparison September 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, IVTY has a market cap of 0. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while IVTY trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas IVTY's P/E ratio is -3.80. In terms of profitability, ATRS's ROE is +0.31%, compared to IVTY's ROE of -2.40%. Regarding short-term risk, ATRS is more volatile compared to IVTY. This indicates higher risk in terms of short-term price fluctuations for ATRS.Check IVTY's competition here
Hill-Rom Holdings, Inc. (NYSE: HRC)
ATRS vs HRC Comparison September 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, HRC has a market cap of 0. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas HRC's P/E ratio is 41.92. In terms of profitability, ATRS's ROE is +0.31%, compared to HRC's ROE of +0.14%. Regarding short-term risk, ATRS is more volatile compared to HRC. This indicates higher risk in terms of short-term price fluctuations for ATRS.Check HRC's competition here